Fig. 1. Regulation of caspase‐3 activity and BrdU incorporation in Tacrolimus-, Sirolimus- and Everolimus-treated HepG2 (A and B, respectively), Huh7 (C and D, respectively) and primary human hepatocytes (E and F, respectively). Apoptosis and cell proliferation were determined using commercial caspase‐3 activity and BrdU incorporation assays respectively as described in Material and Methods. The variables were evaluated at 24 h after treatment administration (0, 10 nM, 10 µM, 100 µM). Results are expressed as mean ± SEM of five independent experiments. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 between control and immunosuppressant‐treated cells. The groups with different letters (a, b, c or d) were significantly different (p ≤ 0.05).